Relative dose intensity of first-line triplet chemotherapy in metastatic colorectal cancer
-
Published:2024-06
Issue:
Volume:
Page:
-
ISSN:1590-8658
-
Container-title:Digestive and Liver Disease
-
language:en
-
Short-container-title:Digestive and Liver Disease
Author:
Hoba JulienORCID, Grancher AdrienORCID, Hautefeuille VincentORCID, Turpin AnthonyORCID, Bouhier-Leporrier Karine, Galais Marie-Pierre, Bignon Anne-Laure, Di Fiore Aude, Desgrippes Romain, Miglianico Laurent, Avisse Benoit, Baconnier Mathieu, Lam You-Heng, Dutherage Marie, Sefrioui David, Malicot Karine LeORCID, Phelip Jean-Marc, Michel Pierre, Gillibert André, Di Fiore Frédéric
Reference17 articles.
1. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up;Cervantes;Ann Oncol Off J Eur Soc Med Oncol,2023 2. Metastatic colorectal cancer (mCRC): french intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR);Phelip;Dig Liver Dis,2019 3. [Descriptive epidemiology of cancer in metropolitan France: incidence, survival and prevalence];Cowppli-Bony;Bull Cancer (Paris),2019 4. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer;Loupakis;N Engl J Med,2014 5. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study;Cremolini;Lancet Oncol,2015
|
|